Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

Reducing the Impact of Chemotherapy-Induced Myelosuppression

September 16th 2020

CDK4/6 Inhibitors & Myelopreservation in Other Cancers

September 16th 2020

CDK4/6 Inhibitors for SCLC: Trials of Interest

September 16th 2020

Chemotherapy-Induced Myelosuppression in SCLC: CDK4/6 Inhibition

September 16th 2020

Analyses of CDK4/6 Inhibitors for Myelopreservation

September 16th 2020

CDK4/6 Inhibitors and Myelopreservation

September 16th 2020

Chemotherapy-Induced Myelosuppression & COVID-19

September 16th 2020

Management of Chemo-Induced Myelosuppression

September 16th 2020

Chemotherapy Use & Chemotherapy-Induced Myelosuppression

September 16th 2020

Dr. Lyman on G-CSF Biosimilars and Potential Impact on the Market

October 1st 2019

Gary H. Lyman, MD, MPH, discusses granulocyte colony-stimulating factor biosimilars and their impact on the market.

Dr. Lyman on Challenges with Biosimilar Policies

September 25th 2019

Gary H. Lyman, MD, MPH, discusses challenges in biosimilar policies.

Dr. Lyman on Rituximab Biosimilars in Non-Hodgkin Lymphoma

September 19th 2019

Gary H. Lyman, MD, MPH, senior lead, Health Care Quality and Policy, Hutchinson Institute for Cancer Outcomes Research, member, Cancer Prevention Program, Public Health Services Division, and member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the use of rituximab (Rituxan) biosimilars in the treatment of patients with non-Hodgkin lymphoma (NHL).

Dr. Lyman on Educational Initiatives Regarding the Use of Biosimilars in Oncology

September 12th 2019

Gary H. Lyman, MD, MPH, senior lead, Health Care Quality and Policy, Hutchinson Institute for Cancer Outcomes Research, member, Cancer Prevention Program, Public Health Services Division, and member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses educational initiatives regarding the use of biosimilars in oncology.

Dr. Lyman on Educating Physicians About Biosimilars in Oncology

August 30th 2019

Gary H. Lyman, MD, MPH, discusses educating physicians about biosimilars in oncology.

Dr. Lyman on Biosimilars Reducing Healthcare Costs in the United States

August 8th 2019

Gary H. Lyman, MD, MPH, senior lead, Health Care Quality and Policy, Hutchinson Institute for Cancer Outcomes Research, member, Cancer Prevention Program, Public Health Services Division, and member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the presence of biosimilars on the market and their potential to reduce healthcare costs in the United States.

Dr. Lyman on the Epoetin Alfa Biosimilar

March 30th 2019

Gary H. Lyman, MD, MPH, medical oncologist, Fred Hutchinson Cancer Research Center, discusses the epoetin alfa biosimilar.

Dr. Lyman on the Process for Approving Biosimilars

March 22nd 2019

Gary H. Lyman, MD, MPH, medical oncologist, Fred Hutchinson Cancer Research Center, discusses the differences in approving a biosimilar and the original biologic product during the 2019 NCCN Annual Conference.